T helper lymphocyte response to respiratory syncytial virus and its components in patients with respiratory allergy and nonatopic controls

International Archives of Allergy and Immunology

Volumn 147, Issue 2, 2008, Pages 110-116

  Shimojo, Naoki ^a   Katsuki, Toshiyuki ^a   Tateno, Noriko ^a   Tomiita, Minako ^a   Kohno, Yoichi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Allergy; Cytokine; F protein; G protein; Respiratory syncytial virus; T cell line

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; PROTEIN F; PROTEIN G; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; ARTICLE; ATOPY; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL LINE; CELL SPECIFICITY; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT ALLERGY;

ANTIGENS, VIRAL; CELL LINE; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOGLOBULIN E; INTERFERON TYPE II; INTERLEUKIN-4; MALE; RESPIRATORY HYPERSENSITIVITY; RESPIRATORY SYNCYTIAL VIRUSES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 51849116058     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000135697     Document Type: Article

References (30)

1. Ogra PL: Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004;5(suppl A):S119-S126.
2. Stein RT, Sherrill D, Morgan WJ, et al: Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541-545.
3. Sigurs N, Gustafsson PM, Bjarnason R, et al: Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171:137-141.
4. Schauer U, Hoffjan S, Bittscheidt J, et al: RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life. Eur Respir J 2002;20:1277-1283.
5. Wenzel SE, Gibbs RL, Lehr MV, Simoes EA: Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med 2002;112:627-633.
6. Collins PL, McIntosh K, Chanock RM: Respiratory syncytial virus; in Fields BN, Knipe DM, Howley PM (eds): Fields' Virology, ed 3. Philadelphia, Raven Publishers, 1996, pp 1313-1351.
7. Psarras S, Papadopoulos NG, Johnston SL Pathogenesis of respiratory syncytial virus bronchiolitis-related wheezing. Paediatr Respir Rev 2004;5(suppl A):S179-S184.
8. Blanco-Quiros A, Gonzalez H, Arranz E, Lapena S: Decreased interleukin-12 levels in umbilical cord blood in children who developed acute bronchiolitis. Pediatr Pulmonol 1999;28:175-180.
9. Trefny P, Stricker T, Baerlocher C, Sennhauser FH: Family history of atopy and clinical course of RSV infection in ambulatory and hospitalized infants. Pediatr Pulmonol 2000;30:302-306.
10. Harris J, Werling D: Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol 2003;5:671-680.
11. Alwan WH, Record FM, Openshaw PJ: Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J Immunol 1993;150:5211-5218.
12. Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, Openshaw PJ: Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J Immunol 1998;161:6215-6222.
13. Stark JM, McDowell SA, Koenigsknecht V, et al: Genetic susceptibility to respiratory syncytial virus infection in inbred mice. J Med Virol 2002;67:92-100.
14. Jackson M, Scott R: Different patterns of cytokine induction in cultures of respiratory syncytial (RS) virus-specific human TH cell lines following stimulation with RS virus and RS virus proteins. J Med Virol 1996;49:161-169.
15. Shimojo N, Kohno Y, Katsuki T, Hoshioka A, Honma K, Saito K, Niimi H: Diminished interferon-gamma (IFN-gamma) production by bacterial antigen-specific T cells in atopic patients. Clin Exp Immunol 1996;106:62-66.
16. Ebner C, Siemann U, Najafian N, Scheiner O, Kraft D: Characterization of allergen (Bet v 1)-specific T cell lines and clones from nonallergic individuals. Int Arch Allergy Immunol 1995;107:183-185.
17. Graham BS, Johnson TR, Peebles RS: Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 2000;48:237-247.
18. de Waal L, Yuksel S, Brandenburg AH, et al: Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein. J Virol 2004;78:1775-1781.
19. Pala P, Bjarnason R, Sigurbergsson F, Metcalfe C, Sigurs N, Openshaw PJ: Enhanced IL-4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. Eur Respir J 2002;20:376-382.
20. Pala P, Message SD, Johnston SL, Openshaw PJ: Increased aeroallergen-specific interleukin-4-producing T cells in asthmatic adults. Clin Exp Allergy 2002;32:1739-1744.
21. Matsuse H, Behera AK, Kumar M, Rabb H, Lockey RF, Mohapatra SS: Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness. J Immunol 2000;164:6583-6592.
22. Makela MJ, Tripp R, Dakhama A, et al: Prior airway exposure to allergen increases virus-induced airway hyperresponsiveness. J Allergy Clin Immunol 2003;112:861-869.
23. Johnson TR, Graham BS: Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 1999;73:8485-8495.
24. Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson LJ: Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 1999;73:7099-7107.
25. Elliott MB, Pryharski KS, Yu Q, et al: Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. J Virol 2004;78:8446-8454.
26. Darville T, Yamauchi T: Respiratory syncytial virus. Pediatr Rev 1998;19:55-61.
27. Johnson TR, Parker RA, Johnson JE, Graham BS: IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol 2003;174:2037-2045.
28. Schwarze J, Schauer U: Enhanced virulence, airway inflammation and impaired lung function induced by respiratory syncytial virus deficient in secreted G protein. Thorax 2004;59:517-521.
29. Bont L, Versteegh J, Swelsen WT, et al: Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res 2002;52:363-367.
30. Chang J, Braciale TJ: Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat Med 2002;8:54-60.